Abstract 4820
Background
Immune checkpoint inhibitors improve survival of patients with advanced melanoma. Combination anti-PD1 and anti-CTLA4 therapy improves the response rate compared to single agent anti-PD1, at the expense of far greater toxicity. While efforts have been made to identify biomarkers to predict treatment response, there are no biomarkers to predict for immunotherapy toxicity.
Methods
198 plasma samples from 99 patients (discovery cohort – 50 patients, validation cohort – 49 patients) receiving combination anti-PD1 (nivolumab or pembrolizumab) and anti-CTLA4 (ipilimumab) were studied. The expression of 65 cytokines, measured at baseline (PRE) and early during treatment (EDT: week 1-3), was correlated with immune-related toxicity, defined as toxicity that warranted discontinuation of treatment and administration of high dose steroids (≥ 50mg PO prednisolone equivalent), within 6 months of starting treatment (hypophysitis requiring steroid replacement was excluded).
Results
Toxicity rates were comparable between the discovery and validation cohorts, 21/50 (42%) and 22/49 (45%) respectively. The median expression of all 65 cytokines was significantly higher in patients with immune-related toxicity, compared to patients without toxicity in both the discovery cohort (PRE; p = 0.01, EDT; p < 0.01) and validation cohort (PRE; p = 0.03, EDT; p = 0.02). In addition, the median expression of six pro-inflammatory cytokines associated with autoimmune disease (IFN, IL-2, IL-17A, IL-1α, IL-1β, IL12) was significantly higher at baseline and EDT in patients with toxicity; discovery (PRE and EDT, p < 0.01) and validation (PRE, p < 0.01; EDT, p = 0.01). Expression of FGF-2, IL-12P70, IL13, IL-1 β, IL-2, MIL-1β and VEGF-A was also significantly higher in patients with toxicity at PRE and EDT, in both the discovery and validation cohorts, compared to patients without toxicity.
Conclusions
Elevated levels of circulating cytokines at baseline and EDT predict development of immune-related toxicity. Pre-treatment measurement of circulating inflammatory cytokines may have an important role in treatment selection for metastatic melanoma patients.
Clinical trial identification
Legal entity responsible for the study
Macquarie University.
Funding
National Health and Medical Research Council.
Editorial Acknowledgement
Disclosure
A.M. Menzies: Consultant or advisory role: BMS, MSD, Novartis, Roche, Pierre-Fabre; Honoraria: BMS, MSD, Novartis, Roche. M.S. Carlino: Consultant or advisory role: MSD, BMS, Amgen, Novartis; Honoraria: BMS, Novartis, MSD A. Guminski: Consultant or advisory role: BMS, Roche, Sun Pharma, Merck KgA Travel support: BMS, Sun Pharma. R. Kefford: Consultant or advisory role: BMS, Merck; Honoraria: BMS Conference attendance: BMS, Amgen. G.V. Long: Consultant or advisory role: BMS, Novartis, Roche, Amgen, Pierre Fabre, MSD, Array; Honoraria: BMS, MSD, Roche, Novartis, Incycte. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract